The company had run into trouble in a scandal over its accounting practices in 2004 and went into bankruptcy in 2005 after selling its pharmaceutical division to Xanodyne.
The company had run into trouble in a scandal over its accounting practices in 2004. The company went into bankruptcy in 2005 after. The company was selling its pharmaceutical division to Xanodyne.